Marpaung Blondina, Ginting Andi Raga, Sjah Ok Moehad
Division of Rheumatology, Faculty of Medicine Universitas of Sumatera Utara, Medan, Indonesia.
Open Access Maced J Med Sci. 2018 Aug 14;6(8):1323-1327. doi: 10.3889/oamjms.2018.315. eCollection 2018 Aug 20.
Midkine (MK) induces inflammation and could inhibit inducible regulatory T cell differentiation. These reports suggest that MK may play a role in the pathogenesis of autoimmune disease including SLE, but data about MK in SLE patients was still limited, and the role of Midkine in SLE is largely unknown.
The purpose of this study was to compare serum level MK in SLE patients and control, also analysed the relationship between the serum MK level and disease activity in SLE.
This cross-sectional study was conducted in Adam Malik Hospital from January-June 2017. Diagnosis of SLE was established according to the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria, and disease activity was assessed using the Mexican Systemic lupus erythematosus disease activity index (MEX-SLEDAI). Subjects with evidence of malignancy and systemic disease (pulmonary, kidney, liver, metabolic disorder, etc.) were excluded. Data analysis was performed using SPSS 22nd version. P < 0.05 was considered statistically significant.
There were 90 subjects and divided into 2 groups: SLE patients group (n=40) and healthy control groups (n = 50). Midkine levels were increased in the serum of SLE patients compared by health control. There was a significant difference in the median serum Midkine levels between SLE patients and healthy control (P < 0.001). Elevated Midkine serum levels were a significant difference between active disease and remission (P = 0.018).
Elevated Midkine serum level could be a marker of SLE disease activity and have a role in the pathogenesis of SLE.
中期因子（MK）可诱导炎症反应，并可能抑制诱导性调节性T细胞分化。这些报道提示MK可能在包括系统性红斑狼疮（SLE）在内的自身免疫性疾病发病机制中发挥作用，但关于SLE患者中MK的数据仍然有限，且中期因子在SLE中的作用很大程度上尚不清楚。
本研究旨在比较SLE患者与对照组的血清MK水平，并分析血清MK水平与SLE疾病活动度之间的关系。
本横断面研究于2017年1月至6月在亚当·马利克医院进行。根据系统性红斑狼疮国际协作临床组（SLICC）分类标准确诊SLE，并使用墨西哥系统性红斑狼疮疾病活动指数（MEX-SLEDAI）评估疾病活动度。排除有恶性肿瘤和系统性疾病（肺部、肾脏、肝脏、代谢紊乱等）证据的受试者。使用SPSS 22版进行数据分析。P<0.05被认为具有统计学意义。
共有90名受试者，分为2组：SLE患者组（n = 40）和健康对照组（n = 50）。与健康对照组相比，SLE患者血清中的中期因子水平升高。SLE患者与健康对照组之间的血清中期因子水平中位数存在显著差异（P<0.001）。疾病活动期与缓解期之间的中期因子血清水平升高存在显著差异（P = 0.018）。
血清中期因子水平升高可能是SLE疾病活动的一个标志物，并在SLE发病机制中起作用。
